Scroll for more



Silvia Taylor
Senior Vice President, Investor Relations and Corporate Affairs


Ms. Taylor became our Senior Vice President of Investor Relations and Corporate Affairs in June 2012, with responsibility for investor relations, corporate communications and government affairs. Prior to joining Sucampo, she held positions of increasing responsibility at MedImmune LLC, the global biologics arm of AstraZeneca, including head of marketing responsible for the commercialization of the company’s RSV and influenza franchises.

From 1999 to 2007, Ms. Taylor worked at Pfizer, where she served in various brand and consumer marketing roles for the company, among them Director of Marketing and launch captain for several of the company’s largest brands. Prior to Pfizer, Ms. Taylor held a variety of public relations and communications roles in agency and non-profit settings from 1993 to 1998.

Ms. Taylor is an honorary member of the Board of Directors of the S&R Foundation.

Ms. Taylor earned a bachelor’s degree in foreign affairs from University of Virginia and a master’s degree in business administration with concentrations in marketing and management from Columbia Business School at Columbia University.

Contact Us
Tel: +1-301-961-3400

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.